Xlife Sciences AG: Successful General Assembly and New Trading Hours on the
Sparks Segment of SIX

Xlife Sciences AG / Key word(s): AGMEGM
Xlife Sciences AG: Successful General Assembly and New Trading Hours on the
Sparks Segment of SIX

28.06.2024 / 18:00 CET/CEST

---------------------------------------------------------------------------

Zurich, 28th of June 2024: Xlife Sciences AG (SIX: XLS), a leading company
in the development and commercialization of technologies and therapies in
the life sciences sector, successfully held its annual general meeting on
June 28, 2024, in Zurich. A total of 3'059'977 voting shares, representing
53.65% of the total share capital, were represented at the meeting. All
proposals by the Board of Directors were approved.

David L. Deck, Chairman of the Board of Directors of Xlife Sciences AG,
commented: «We thank all our valued shareholders for their trust. Looking
back on the past financial year, we were able to achieve significant
milestones. I would also like to thank all the project companies and the
Xlife Sciences team for their tireless efforts.»

Oliver R. Baumann, CEO and member of the Board of Directors, added: «The
board, the management team, and all employees of our 25 project companies
remain committed to creating value for all stakeholders of Xlife Sciences
AG. The progress we have made in the first half of 2024 includes, among
other things, the commercialization of the AI-powered software
«Prostate.Carcinoma.ai» for radiology (FUSE-AI GmbH), the strategic merger
between palleos healthcare GmbH and OCT Clinical GmbH, and the expansion of
cooperation with the Department of Health of Abu Dhabi, as well as
partnerships with Thermo Fisher Scientific and Masdar City.»

We are also pleased to inform you that SIX Swiss Exchange AG will normalize
trading hours in the «Sparks» trading segment starting July 1, 2024. This
will allow our shareholders to trade from 9:00 AM to 5:20 PM (CET), with a
closing auction from 5:20 PM to 5:30 PM (CET) and subsequent trading at the
closing price until 5:40 PM (CET). This adjustment aims to optimize trading
activities and especially facilitate entry for institutional investors.
Further details can be found in SIX Swiss Exchange Notice No. 17/2024.

Financial calendar

Half-Year Report 2024 19 September 2024
Xlife Sciences AG,
Talacker 35,
8001 Zurich,
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch,
Commercial Register Zurich CHE-330.279.788
Stock Exchange: SIX Swiss Exchange

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis
Fink, dennis.fink@xlifesciences.ch

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on
the value development and commercialization of promising research projects
from universities and other research institutions in the life sciences
sector, with the aim of providing solutions for high unmet medical needs and
a better quality of life. The goal is to bridge research and development to
healthcare markets. Xlife Sciences takes carefully selected projects in the
four areas of technological platforms, biotechnology/ therapies, medical
technology, and artificial intelligence/digital health to the next stage of
development, and participates in their subsequent performance. For more
information, visit www.xlifesciences.ch

Disclaimer

Some of the information contained in this media release contains
forward-looking statements. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance and
involve risks and uncertainties, and that actual results may differ
materially from those in the forward-looking statements as a result of
various factors. Xlife Sciences undertakes no obligation to publicly update
or revise any forward-looking statements.


---------------------------------------------------------------------------

End of Media Release

---------------------------------------------------------------------------

   Language:       English
   Company:        Xlife Sciences AG
                   Talacker 35
                   8001 Zürich
                   Switzerland
   Phone:          +41 44 385 84 60
   E-mail:         info@xlifesciences.ch
   Internet:       www.xlifesciences.ch
   ISIN:           CH0461929603
   Valor:          A2PK6Z
   Listed:         SIX Swiss Exchange
   EQS News ID:    1936159

End of News EQS News Service
---------------------------------------------------------------------------

1936159 28.06.2024 CET/CEST